about
Transportation of berberine into HepG2, HeLa and SY5Y cells: a correlation to its anti-cancer effectPhase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerEfficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach.Reverse the Resistance to PARP Inhibitors.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.Renal Drug Transporters and Drug Interactions.A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.PARP inhibitors: the journey from research hypothesis to clinical approval.Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response.Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
P2860
Q28544999-FA61A7E4-C86D-48C5-A2FE-572726E34847Q33429434-738E85D9-B23A-4449-B641-FEB9F5077302Q35799917-CD520AEA-D4BD-4BF4-AFB7-EB9B0A42F938Q35909731-02DEE81E-62BB-42A0-86D3-CD464CF4DF9FQ36259861-54715EC3-24FA-4E5E-B259-2AA33170B2F6Q37675896-0734321F-85D6-4A56-B7D4-34E6AC302561Q38596368-FF1D00E5-063A-49F1-9C87-99B7470CAA00Q38758230-F1123F13-0F3F-42B4-B1C9-CC3F8FB83CA7Q38874006-632AC53C-02D9-46F8-B8A1-2A3BFBCE9C80Q39140289-1FB3D745-DD0D-4592-BA3B-0D44EB1AAFB6Q41316932-C680273D-746C-4D53-A1B2-AD6B20A63032Q43042008-F0A7D1E2-A9C2-414E-BBD3-ED2EF8DF4CDBQ53682668-CB3141C7-20C6-4DD6-8DA5-3A71C08F793DQ53776619-18DFAC53-C86B-4EF7-9255-2A90A4008A1EQ58801181-AF09A3B1-57DF-47E3-A939-9FA1394ABF57
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
PARP Inhibitors as P-glyoprotein Substrates.
@en
PARP Inhibitors as P-glyoprotein Substrates.
@nl
type
label
PARP Inhibitors as P-glyoprotein Substrates.
@en
PARP Inhibitors as P-glyoprotein Substrates.
@nl
prefLabel
PARP Inhibitors as P-glyoprotein Substrates.
@en
PARP Inhibitors as P-glyoprotein Substrates.
@nl
P2093
P50
P356
P1476
PARP Inhibitors as P-glyoprotein Substrates
@en
P2093
Bryan T Hennessy
Denise Lawlor
Julien Thery
Patricia Martin
P304
P356
10.1002/JPS.23952
P407
P577
2014-04-03T00:00:00Z